02.12.2014 Views

Innovation in European healthcare – what can Sweden learn? - LIF

Innovation in European healthcare – what can Sweden learn? - LIF

Innovation in European healthcare – what can Sweden learn? - LIF

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Central Changes <strong>in</strong> the German <strong>healthcare</strong> System<br />

2011/12 II<br />

• The law on the reform of the SHI care structure (GKV-<br />

Versorgungsstrukturgesetz) became effective <strong>in</strong> the beg<strong>in</strong>n<strong>in</strong>g of 2012<br />

• Most important new regulations:<br />

– Insur<strong>in</strong>g outpatient physician care <strong>in</strong> densely populated regions by better reimbursement and better<br />

work<strong>in</strong>g conditions<br />

– Regionalization of the plann<strong>in</strong>g process for SHI doctors<br />

– Regional associations of SHI doctors (Kassenärztliche Vere<strong>in</strong>igungen) get the right to decide about<br />

the distribution of SHI reimbursement between the SHI doctors <strong>in</strong> the region<br />

– Only SHI outpatient physicians and hospitals have the right to found and run Medical Treatment<br />

Centers (Mediz<strong>in</strong>ische Versorgungszentren MVZ)<br />

– Highly specialized outpatient care (e.g. outpatient <strong>can</strong>cer treatment) <strong>can</strong> be carried out by<br />

specialized outpatient physicians and hospitals with specialized departments<br />

– M<strong>in</strong>or reform of the Federal Jo<strong>in</strong>t Committee (Geme<strong>in</strong>samer Bundesausschuss G-BA)<br />

– The Federal Jo<strong>in</strong>t Committee has now the possibility of test<strong>in</strong>g exam<strong>in</strong>ation and treatment methods<br />

whose benefit has not yet been sufficiently proved, but which show potential as a treatment<br />

alternative. A request <strong>can</strong> be submitted by<br />

• the manufacturer of a medical product whose use signifi<strong>can</strong>tly depends on the application of a new<br />

exam<strong>in</strong>ation or treatment method<br />

• Companies that are not providers of a new method, but that have an economic <strong>in</strong>terest <strong>in</strong> its provision by the<br />

statutory health <strong>in</strong>surance providers<br />

45

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!